Suvorexant for primary insomnia: A systematic review and meta-analysis of randomized placebo-controlled trials

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Kishi, Taro ^a   Matsunaga, Shinji ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUVOREXANT; AZEPINE DERIVATIVE; HYPNOTIC AGENT; TRIAZOLE DERIVATIVE;

ABNORMAL DREAMING; AGE DISTRIBUTION; ARTICLE; CLINICAL EFFECTIVENESS; DAYTIME SOMNOLENCE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND INSOMNIA; RISK ASSESSMENT; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SLEEP QUALITY; SLEEP TIME; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA; FEMALE; MALE; MIDDLE AGED; SLEEP INITIATION AND MAINTENANCE DISORDERS;

AZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP AIDS, PHARMACEUTICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84943247365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136910     Document Type: Article

References (24)

1. Ohayon MM, Partinen M. Insomnia and global sleep dissatisfaction in Finland. Journal of sleep research. 2002;11(4):339-46. PMID: 12464102.
2. Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? Journal of affective disorders. 2003;76(1-3):255-9. PMID: 12943956.
3. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep medicine. 2014;15(4):385-92. doi: 10.1016/j.sleep. 2013.11.788 PMID: 24656909.
4. Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS drugs. 2014;28(9):799-816. doi: 10.1007/s40263-014-0198-7 PMID: 25168785.
5. Lader M. Benzodiazepines revisited-will we ever learn? Addiction. 2011;106(12):2086-109. doi: 10. 1111/j.1360-0443.2011.03563.x PMID: 21714826.
6. Rapoport MJ, Lanctot KL, Streiner DL, Bedard M, Vingilis E, Murray B, et al. Benzodiazepine use and driving: a meta-analysis. The Journal of clinical psychiatry. 2009;70(5):663-73. doi: 10.4088/JCP. 08m04325 PMID: 19389334.
7. Krystal AD, Benca RM, Kilduff TS. Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. The Journal of clinical psychiatry. 2013;74 Suppl 1:3-20. doi: 10.4088/JCP.13011su1c PMID: 24107804.
8. Dubey AK, Handu SS, Mediratta PK. Suvorexant: The first orexin receptor antagonist to treat insomnia. Journal of pharmacology & pharmacotherapeutics. 2015;6(2):118-21. doi: 10.4103/0976-500X. 155496 PMID: 25969666; PubMed Central PMCID: PMC4419247.
9. Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee PMID: 23197752.
10. Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2014;13(5):461-71. doi: 10.1016/S1474-4422 (14) 70053-5 PMID: 24680372.
11. Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, et al. Suvorexant in Patients with Insomnia: Results from Two 3-Month Randomized Controlled Clinical Trials. Biological psychiatry. 2014. doi: 10.1016/j.biopsych.2014.10.003 PMID: 25526970.
12. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration. 2011; www.cochrane-handbook.org.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj. 2009;339:b2535. Epub 2009/07/23. doi: 10.1136/bmj.b2535 PMID: 19622551; PubMed Central PMCID: PMC2714657.
14. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep medicine. 2001;2(4):297-307. PMID: 11438246.
15. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery, 2nd ed. Chevy Chase, Md, National Institute of Mental Health. 1970. Epub 1970.
16. Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. Journal of affective disorders. 1990;19(1):53-61. PMID: 1971833.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. Epub 1986/09/01. PMID: 3802833.
18. Merck. 2014; Available: http://www.merck.com/product/usa/pi-circulars/b/belsomra/belsomra-pi.pdf.
19. Etori K, Saito YC, Tsujino N, Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Frontiers in neuroscience. 2014;8:8. doi: 10.3389/fnins.2014.00008 PMID: 24550770; PubMed Central PMCID: PMC3907770.
20. Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Frontiers in neuroscience. 2014;8:57. doi: 10.3389/fnins.2014.00057 PMID: 24834023; PubMed Central PMCID: PMC4018553.
21. Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV. Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Frontiers in neuroscience. 2014;8:36. doi: 10.3389/fnins.2014. 00036 PMID: 24616658; PubMed Central PMCID: PMC3934415.
22. Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, et al. LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Frontiers in neuroscience. 2014;8:5. doi: 10.3389/fnins.2014.00005 PMID: 24478625; PubMed Central PMCID: PMC3904085.
23. Soehner AM, Kaplan KA, Harvey AG. Insomnia comorbid to severe psychiatric illness. Sleep medicine clinics. 2013;8(3):361-71. doi: 10.1016/j.jsmc.2013.04.007 PMID: 25302060; PubMed Central PMCID: PMC4187404.
24. Citrome L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(12):1429-41. doi: 10.1111/ijcp. 12568 PMID: 25231363